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Evidence is accumulating that long term compliance (LTC)
may be better with newer antihypertensive agents that have
better safety profiles.
 
OBJECTIVES:
 
 To evaluate whether newer, better tolerated
drugs improve LTC with antihypertensive medications.
 
METHODS:
 
 We used pharmacy and healthcare adminis-
trative claims data from United Healthcare (1994–1997)
to compare retrospectively LTC by antihypertensive drug
class. The study population consisted of hypertensive pa-
tients on monotherapy from six U.S. HMOs, and enrolled
in the plan for the duration of the 18 months of follow up.
We assessed patients on diuretics, beta-blockers (BB),
CCBs, ACEs, and ARBs. We estimated a two-stage model
that measures LTC by drug class while adjusting for physi-
cian’s decisions to select a particular drug due to the pa-
tient’s medical history. Logistic regressions were used first
to estimate physician’s prescribing decisions based on the
patient’s medical profile. Second, Cox regression was used
to estimate LTC for each drug class while controlling for
physician’s choices, plan type, HMO geographic location,
and patient demography.
RESULTS: The study entry criteria provided for analysis
of 9,002 patients with mean age of 54 years and 52%
male. By drug, patients were distributed as diuretics 342
(3.7%), BB 316 (3.5%), ACEs 3516 (39.0), CCBs 4514
(50.1%), and ARBs 314 (3.4%). LTC was significantly
better for patients treated with ACEs and CCBs compared
to diuretics and BB (61% vs 37% at 1 yr). ARBs showed
the most favorable LTC (90% at 1 yr). The log rank tests
indicated that LTC were statistically different (better) for
patients treated with ACEs and CCBs compared to diuret-
ics and BB (p  0.001) and statistically different (better)
for patients treated with ARBs compared to ACEs and
CCBs (p  0.001).
CONCLUSION: These results indicate that choice of anti-
hypertensives plays an important role in LTC and newer
agents with improved tolerability like ARBs provided the
best LTC.
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OJECTIVES:
 
 To assess the relative cost-efficacy of low-
molecular-weight heparin thromboprophylaxis using dalte-
parin continued beyond hospitalization and warfarin during
hospitalization in patients undergoing total hip replace-
ment (THR) surgery.
METHODS: Patients in this double blind, multi-center
clinical trial received either initial (P1) or extended (P2)
thromboprophylaxis post arthroplasty. P1 patients were
randomized to receive dalteparin pre-operatively (Dpre),
dalteparin post-operatively (Dpost), or warfarin (Warf) for
6  2 days. In P2, patients continued with dalteparin (Dpre,
Dpost) or placebo (Warf) through 35  2 days. Economic
outcomes were based on medical interventions associated
primarily with suspected deep vein thrombosis (DVT) and/
or symptoms of pulmonary embolism (PE) with onset dur-
ing the study. Total inpatient length of stay (LOS) was in-
cluded in calculations of total costs. The thromboprophy-
laxis treatment regimen and a composite intervention for
all major events were valued based on local resource costs.
These costs were then applied to specific patient cases.
RESULTS: A total of 425 patients in the United States
(U.S.) and 705 patients in Canada were in P1; 93 U.S. and
532 Canadian patients continued to P2. The incidence of
suspected DVT was higher in the Warf group in P1 and P2
(p  .002; p  .001). No differences were detected in
LOS. In P1 and P2 respectively, more dalteparin patients
received blood transfusions (p  .001; p  .001). Overall
per patient costs (U.S. dollars) were similar in P1 (Dpre 
$6667, Dpost  $6467, Warf  $6339) and in P2 (Dpre 
$6060, Dpost  $5976, Warf  $5718). Incremental cost-
efficacy for dalteparin ranged (in U.S. dollars) from $1799
to $4661. An analysis by country yielded similar results.
